All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

ifosfamide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antineoplastic, alkylating agents, (beta-chloroethyl)amine derivatives	1421	3778-73-2

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: ifosfamide holoxan ifomide ifosfamid ifosfomide ifosphamide iphosphamide isoendoxan isofosfamide isophosphamide mitoxana naxamide	Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent. Molecular weight: 261.08 Formula: C7H15Cl2N2O2P CLOGP: 0.92 LIPINSKI: 0 HAC: 4 HDO: 1 TPSA: 41.57 ALOGS: -1.24 ROTB: 5 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

None

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	100 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	10 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	113.59 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	92 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.62 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	1.10 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	1 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	6.60 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Dec. 30, 1988	FDA	BAXTER HLTHCARE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	1316.21	26.25	634	16127	117815	63354446
Encephalopathy	788.99	26.25	318	16443	38302	63433959
Neutropenia	648.55	26.25	460	16301	174545	63297716
Disease progression	559.47	26.25	367	16394	122391	63349870
Mucosal inflammation	491.23	26.25	242	16519	46686	63425575
Myelodysplastic syndrome	430.11	26.25	163	16598	16591	63455670
Ovarian failure	427.88	26.25	93	16668	1217	63471044
Bone marrow failure	420.62	26.25	188	16573	29102	63443159
Thrombocytopenia	355.28	26.25	304	16457	150853	63321408
Off label use	349.06	26.25	629	16132	673833	62798428
Acute myeloid leukaemia	338.64	26.25	138	16623	17009	63455252
Pancytopenia	310.76	26.25	234	16527	96699	63375562
Haematotoxicity	276.35	26.25	101	16660	9275	63462986
Product use in unapproved indication	252.74	26.25	272	16489	178808	63293453
Neurotoxicity	221.43	26.25	102	16659	16888	63455373
Myelosuppression	200.50	26.25	106	16655	23597	63448664
Malignant neoplasm progression	200.37	26.25	169	16592	81952	63390309
Second primary malignancy	174.21	26.25	69	16692	7884	63464377
Febrile bone marrow aplasia	162.01	26.25	64	16697	7261	63465000
Cardiotoxicity	156.62	26.25	65	16696	8373	63463888
Diffuse large B-cell lymphoma recurrent	153.34	26.25	46	16715	2274	63469987
Toxic encephalopathy	129.98	26.25	53	16708	6526	63465735
Aplasia	125.91	26.25	46	16715	4213	63468048
Anaemia	120.09	26.25	249	16512	293181	63179080
Fanconi syndrome	106.88	26.25	31	16730	1361	63470900
Cystitis haemorrhagic	98.14	26.25	38	16723	4085	63468176
Arthralgia	96.88	26.25	17	16744	569693	62902568
Leukopenia	94.28	26.25	109	16652	77181	63395080
Metastases to lymph nodes	84.96	26.25	42	16719	8116	63464145
Pain	82.19	26.25	47	16714	740581	62731680
Premature menopause	78.21	26.25	22	16739	864	63471397
Ascites	77.69	26.25	73	16688	40655	63431606
Fatigue	72.46	26.25	77	16684	887951	62584310
Metastases to peritoneum	72.36	26.25	29	16732	3413	63468848
Renal tubular disorder	72.04	26.25	27	16734	2655	63469606
Neutropenic sepsis	71.76	26.25	48	16713	16390	63455871
Diffuse large B-cell lymphoma refractory	71.09	26.25	22	16739	1208	63471053
Malignant transformation	68.79	26.25	17	16744	400	63471861
Gene mutation	68.48	26.25	23	16738	1642	63470619
Septic shock	68.21	26.25	86	16675	66543	63405718
Posterior reversible encephalopathy syndrome	67.08	26.25	47	16714	17298	63454963
Neoplasm progression	65.12	26.25	63	16698	36365	63435896
Disease recurrence	64.81	26.25	56	16705	27974	63444287
Abdominal discomfort	63.01	26.25	6	16755	320879	63151382
Cytokine release syndrome	62.97	26.25	42	16719	14272	63457989
Headache	60.97	26.25	47	16714	633194	62839067
Ovarian disorder	59.36	26.25	17	16744	713	63471548
Nephrogenic diabetes insipidus	59.02	26.25	18	16743	941	63471320
Pruritus	58.75	26.25	12	16749	361441	63110820
Oligohydramnios	58.17	26.25	30	16731	6336	63465925
Rash	56.07	26.25	40	16721	560831	62911430
Platelet count decreased	55.09	26.25	105	16656	116017	63356244
Fall	54.30	26.25	18	16743	392316	63079945
Weight increased	53.59	26.25	4	16757	260788	63211473
Therapy partial responder	53.57	26.25	34	16727	10624	63461637
Dizziness	52.45	26.25	24	16737	429901	63042360
Leukoerythroblastosis	51.04	26.25	12	16749	227	63472034
Cytopenia	50.93	26.25	34	16727	11567	63460694
Oesophageal candidiasis	49.77	26.25	26	16735	5637	63466624
Nephropathy toxic	49.55	26.25	31	16730	9448	63462813
Salivary gland cancer	48.88	26.25	11	16750	170	63472091
Neutrophil count decreased	48.74	26.25	67	16694	56339	63415922
Foetal death	47.77	26.25	32	16729	10948	63461313
T-cell lymphoma refractory	47.24	26.25	9	16752	57	63472204
Drug hypersensitivity	47.10	26.25	12	16749	310675	63161586
Leukoencephalopathy	46.78	26.25	23	16738	4390	63467871
Contraindicated product administered	45.69	26.25	3	16758	217645	63254616
Swelling	45.02	26.25	9	16752	275369	63196892
Hypersensitivity	44.96	26.25	11	16750	292674	63179587
Peripheral swelling	44.95	26.25	8	16753	265934	63206327
Vena cava thrombosis	44.50	26.25	18	16743	2169	63470092
Systemic lupus erythematosus	43.50	26.25	3	16758	208915	63263346
Tumour lysis syndrome	43.49	26.25	28	16733	8962	63463299
Metastases to breast	43.07	26.25	11	16750	297	63471964
Pneumothorax	42.77	26.25	35	16726	16226	63456035
Pyrexia	42.70	26.25	240	16521	470238	63002023
Multiple organ dysfunction syndrome	42.54	26.25	63	16698	56689	63415572
Dyspnoea	41.87	26.25	69	16692	661244	62811017
Polyneuropathy	41.76	26.25	33	16728	14556	63457705
Neoplasm recurrence	41.24	26.25	18	16743	2620	63469641
Pain in extremity	41.19	26.25	18	16743	331468	63140793
Myeloid leukaemia	40.38	26.25	11	16750	383	63471878
Malaise	39.79	26.25	31	16730	415923	63056338
Insomnia	39.75	26.25	5	16756	215247	63257014
Deafness	39.74	26.25	35	16726	17922	63454339
White blood cell count abnormal	39.29	26.25	23	16738	6219	63466042
Strongyloidiasis	38.83	26.25	14	16747	1234	63471027
Infusion related reaction	38.14	26.25	9	16752	245512	63226749
Periorbital cellulitis	38.05	26.25	12	16749	701	63471560
Sinusitis	37.90	26.25	7	16754	226646	63245615
Amniotic fluid index decreased	36.53	26.25	6	16755	13	63472248
Drug intolerance	36.43	26.25	18	16743	308643	63163618
Cough	36.20	26.25	16	16745	292727	63179534
Lymphoma	35.82	26.25	28	16733	12159	63460102
Foetal growth restriction	35.25	26.25	23	16738	7530	63464731
Subdural hygroma	35.06	26.25	9	16752	248	63472013
Haemophagocytic lymphohistiocytosis	34.71	26.25	26	16735	10601	63461660
Drug resistance	34.26	26.25	36	16725	22897	63449364
Arthropathy	33.82	26.25	10	16751	234782	63237479
Fanconi syndrome acquired	33.65	26.25	12	16749	1024	63471237
Sepsis	32.94	26.25	102	16659	153021	63319240
Vulvovaginitis	32.64	26.25	9	16752	328	63471933
Metastases to lung	32.60	26.25	27	16734	12723	63459538
Amenorrhoea	31.81	26.25	24	16737	9890	63462371
Systemic candida	31.70	26.25	16	16745	3229	63469032
Rhabdomyosarcoma recurrent	31.63	26.25	6	16755	37	63472224
Metastases to liver	31.62	26.25	35	16726	23604	63448657
Delayed puberty	31.36	26.25	7	16754	104	63472157
Discomfort	30.63	26.25	4	16757	167370	63304891
Stem cell transplant	30.34	26.25	13	16748	1809	63470452
Urticaria	30.25	26.25	4	16757	165798	63306463
Escherichia bacteraemia	29.00	26.25	16	16745	3867	63468394
Contusion	28.91	26.25	3	16758	150041	63322220
Blood stem cell transplant failure	28.90	26.25	7	16754	151	63472110
Skin turgor decreased	28.05	26.25	9	16752	556	63471705
Paranasal sinus mucosal hypertrophy	27.96	26.25	5	16756	21	63472240
Candida test positive	27.68	26.25	10	16751	886	63471375
Rectal fissure	26.55	26.25	9	16752	661	63471600

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	1234.14	21.42	897	23112	135952	34796970
Disease progression	560.87	21.42	515	23494	107562	34825360
Neutropenia	487.03	21.42	567	23442	156211	34776711
Encephalopathy	447.81	21.42	287	23722	35032	34897890
Off label use	429.35	21.42	907	23102	418617	34514305
Myelodysplastic syndrome	338.70	21.42	193	23816	19015	34913907
Bone marrow failure	306.03	21.42	211	23798	29042	34903880
Acute myeloid leukaemia	265.41	21.42	162	23847	18108	34914814
Mucosal inflammation	260.06	21.42	214	23795	38408	34894514
Myelosuppression	257.50	21.42	162	23847	19103	34913819
Diffuse large B-cell lymphoma recurrent	256.88	21.42	93	23916	3135	34929787
Thrombocytopenia	254.24	21.42	414	23595	155833	34777089
Product use in unapproved indication	232.55	21.42	341	23668	117158	34815764
Malignant neoplasm progression	209.07	21.42	279	23730	87767	34845155
Diffuse large B-cell lymphoma refractory	207.78	21.42	63	23946	1203	34931719
Haematotoxicity	202.25	21.42	103	23906	8091	34924831
Pancytopenia	195.17	21.42	281	23728	94876	34838046
Second primary malignancy	176.99	21.42	93	23916	7793	34925129
Cytopenia	164.99	21.42	105	23904	12618	34920304
Neurotoxicity	140.76	21.42	109	23900	17901	34915021
Neoplasm progression	135.98	21.42	119	23890	23181	34909741
Toxic encephalopathy	120.91	21.42	63	23946	5186	34927736
Blood lactate dehydrogenase increased	119.50	21.42	110	23899	22880	34910042
Therapy partial responder	116.37	21.42	76	23933	9540	34923382
Neutropenic sepsis	106.87	21.42	83	23926	13684	34919238
Fanconi syndrome	105.64	21.42	41	23968	1679	34931243
Renal tubular disorder	104.87	21.42	55	23954	4588	34928334
Fall	100.76	21.42	11	23998	202874	34730048
Osteosarcoma	100.61	21.42	26	23983	267	34932655
Aplasia	94.19	21.42	51	23958	4537	34928385
Salivary gland cancer	93.58	21.42	25	23984	295	34932627
Febrile bone marrow aplasia	92.36	21.42	62	23947	8147	34924775
Leukopenia	91.75	21.42	159	23850	62697	34870225
Sepsis	85.61	21.42	280	23729	166281	34766641
Nephropathy toxic	78.91	21.42	67	23942	12521	34920401
Stomatitis	76.16	21.42	118	23891	42396	34890526
Disease recurrence	75.19	21.42	83	23926	21407	34911515
Tumour lysis syndrome	72.35	21.42	73	23936	16986	34915936
Cystitis haemorrhagic	71.45	21.42	46	23963	5633	34927289
B-cell lymphoma recurrent	70.88	21.42	25	23984	779	34932143
Neoplasm recurrence	69.60	21.42	33	23976	2216	34930706
Malignant transformation	62.06	21.42	23	23986	828	34932094
Dizziness	61.54	21.42	37	23972	218484	34714438
Myocardial infarction	61.51	21.42	6	24003	121079	34811843
Blood stem cell transplant failure	60.77	21.42	19	23990	403	34932519
Metastases to lung	57.17	21.42	49	23960	9271	34923651
Insomnia	55.93	21.42	4	24005	103903	34829019
Cardiotoxicity	54.92	21.42	39	23970	5609	34927313
Pyrexia	52.93	21.42	400	23609	332613	34600309
Anal inflammation	52.63	21.42	23	23986	1277	34931645
Fanconi syndrome acquired	51.95	21.42	26	23983	1965	34930957
Rash	51.95	21.42	46	23963	222706	34710216
Anaemia	51.33	21.42	304	23705	233031	34699891
Fatigue	50.21	21.42	113	23896	370540	34562382
Therapy non-responder	48.15	21.42	92	23917	39054	34893868
Metastases to muscle	48.07	21.42	14	23995	231	34932691
Azoospermia	47.78	21.42	16	23993	425	34932497
Drug ineffective	47.04	21.42	499	23510	456252	34476670
Treatment failure	47.03	21.42	101	23908	46596	34886326
Metastases to spleen	46.81	21.42	16	23993	453	34932469
Cellulitis gangrenous	46.75	21.42	13	23996	180	34932742
Dyspnoea	46.20	21.42	121	23888	376661	34556261
Transformation to acute myeloid leukaemia	45.94	21.42	18	23991	756	34932166
Delayed puberty	44.66	21.42	13	23996	214	34932708
Cytokine release syndrome	44.49	21.42	66	23943	22811	34910111
Acute lymphocytic leukaemia	44.30	21.42	27	23982	3002	34929920
Ganglioneuroblastoma	44.10	21.42	9	24000	27	34932895
Body height below normal	43.84	21.42	13	23996	229	34932693
Nervous system disorder	43.82	21.42	52	23957	14491	34918431
Rhabdomyosarcoma recurrent	43.77	21.42	11	23998	100	34932822
Myalgia	43.15	21.42	4	24005	84106	34848816
Venoocclusive liver disease	43.09	21.42	39	23970	7927	34924995
Septic shock	42.54	21.42	127	23882	71707	34861215
SARS-CoV-2 test negative	41.14	21.42	18	23991	1002	34931920
Meningitis tuberculous	40.90	21.42	16	23993	669	34932253
Cardiac failure congestive	40.06	21.42	5	24004	83265	34849657
Encephalitis enteroviral	39.99	21.42	11	23998	146	34932776
Arthralgia	39.75	21.42	35	23974	170006	34762916
Diffuse large B-cell lymphoma	39.71	21.42	36	23973	7334	34925588
Bacteraemia	38.51	21.42	57	23952	19660	34913262
Blood pressure increased	38.47	21.42	7	24002	88095	34844827
Device related infection	38.32	21.42	53	23956	17184	34915738
Depression	37.78	21.42	10	23999	97088	34835834
Chest pain	36.29	21.42	21	23988	126741	34806181
Peripheral swelling	35.85	21.42	5	24004	76536	34856386
Bradycardia	35.15	21.42	5	24004	75413	34857509
Metastases to retroperitoneum	34.68	21.42	11	23998	245	34932677
Ameloblastoma	34.60	21.42	9	24000	95	34932827
Post-acute COVID-19 syndrome	34.17	21.42	10	23999	168	34932754
Nasopharyngitis	34.15	21.42	4	24005	69964	34862958
Lymphadenopathy	33.90	21.42	66	23943	28397	34904525
Autoimmune neutropenia	33.67	21.42	11	23998	270	34932652
Weight increased	33.60	21.42	11	23998	93022	34839900
Hepatitis B reactivation	33.58	21.42	25	23984	3866	34929056
Proctalgia	32.90	21.42	29	23980	5694	34927228
Hypogammaglobulinaemia	32.58	21.42	33	23976	7707	34925215
Overdose	32.48	21.42	11	23998	91048	34841874
Basal cell naevus syndrome	31.99	21.42	7	24002	32	34932890
Inappropriate schedule of product administration	31.85	21.42	3	24006	62293	34870629
Lymphoma	31.69	21.42	41	23968	12466	34920456
Drug resistance	30.73	21.42	60	23949	25867	34907055
Headache	30.62	21.42	57	23952	200578	34732344
Ototoxicity	30.40	21.42	18	23991	1899	34931023
Tubulointerstitial nephritis	30.39	21.42	53	23956	20971	34911951
Chromosome analysis abnormal	30.28	21.42	9	24000	160	34932762
Recurrent cancer	30.10	21.42	16	23993	1371	34931551
Adenoviral hepatitis	30.01	21.42	12	23997	532	34932390
Hyperkalaemia	29.26	21.42	6	24003	69383	34863539
Anxiety	29.13	21.42	16	23993	99412	34833510
Renal tubular injury	29.13	21.42	14	23995	969	34931953
Muscle spasms	28.65	21.42	8	24001	74993	34857929
Progressive multifocal leukoencephalopathy	27.92	21.42	34	23975	9730	34923192
Accident	27.87	21.42	25	23984	5022	34927900
Herpes simplex	27.71	21.42	26	23983	5533	34927389
Adenovirus reactivation	27.70	21.42	9	24000	217	34932705
Posterior reversible encephalopathy syndrome	27.39	21.42	34	23975	9920	34923002
Lymphopenia	27.37	21.42	44	23965	16291	34916631
Agranulocytosis	26.87	21.42	54	23955	23767	34909155
Metastases to bone marrow	26.70	21.42	11	23998	527	34932395
Neuroblastoma recurrent	26.51	21.42	8	24001	150	34932772
Respiratory failure	26.10	21.42	145	23864	108427	34824495
Venoocclusive disease	26.05	21.42	19	23990	2848	34930074
Hospitalisation	25.99	21.42	4	24005	56898	34876024
Platelet count abnormal	25.72	21.42	19	23990	2903	34930019
Abdominal discomfort	25.59	21.42	5	24004	59830	34873092
Feeling abnormal	25.58	21.42	6	24003	63229	34869693
Clostridium difficile colitis	24.50	21.42	41	23968	15689	34917233
Neutropenic colitis	24.48	21.42	19	23990	3125	34929797
Scedosporium infection	24.44	21.42	12	23997	870	34932052
Synovial sarcoma metastatic	23.80	21.42	5	24004	18	34932904
Syncope	23.64	21.42	17	23992	91434	34841488
Candida infection	23.47	21.42	43	23966	17672	34915250
Asthenia	23.44	21.42	88	23921	245163	34687759
Aspergillus infection	23.31	21.42	35	23974	12219	34920703
BK virus infection	23.31	21.42	24	23985	5714	34927208
Human herpesvirus 8 infection	23.30	21.42	12	23997	963	34931959
Condition aggravated	23.25	21.42	62	23947	192134	34740788
Pneumonia adenoviral	23.20	21.42	9	24000	368	34932554
Bone sarcoma	22.52	21.42	6	24003	70	34932852
Vomiting	22.35	21.42	264	23745	247357	34685565
Blastic plasmacytoid dendritic cell neoplasia	22.29	21.42	6	24003	73	34932849
Myeloid leukaemia	22.19	21.42	9	24000	414	34932508
Musculoskeletal stiffness	21.97	21.42	3	24006	46677	34886245
Platelet count decreased	21.90	21.42	149	23860	119568	34813354
Immune effector cell-associated neurotoxicity syndrome	21.71	21.42	19	23990	3694	34929228
Hypophosphataemia	21.70	21.42	32	23977	10994	34921928
Urticaria	21.44	21.42	8	24001	62369	34870553

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	2310.11	20.66	1389	35301	229610	79478088
Encephalopathy	1080.78	20.66	555	36135	66842	79640856
Neutropenia	1004.56	20.66	920	35770	286790	79420908
Disease progression	754.67	20.66	646	36044	183716	79523982
Bone marrow failure	669.32	20.66	368	36322	50739	79656959
Myelodysplastic syndrome	666.67	20.66	310	36380	29991	79677707
Off label use	646.22	20.66	1335	35355	905880	78801818
Mucosal inflammation	623.47	20.66	404	36286	75176	79632522
Thrombocytopenia	541.26	20.66	637	36053	264622	79443076
Acute myeloid leukaemia	540.11	20.66	270	36420	30615	79677083
Pancytopenia	457.65	20.66	467	36223	165278	79542420
Malignant neoplasm progression	413.69	20.66	404	36286	135586	79572112
Haematotoxicity	401.99	20.66	178	36512	15341	79692357
Product use in unapproved indication	391.89	20.66	527	36163	249832	79457866
Myelosuppression	381.00	20.66	235	36455	40061	79667637
Second primary malignancy	325.36	20.66	150	36540	14200	79693498
Diffuse large B-cell lymphoma recurrent	320.40	20.66	106	36584	4101	79703597
Neurotoxicity	308.28	20.66	190	36500	32328	79675370
Febrile bone marrow aplasia	225.05	20.66	113	36577	12907	79694791
Fanconi syndrome	221.65	20.66	73	36617	2783	79704915
Toxic encephalopathy	217.68	20.66	106	36584	11334	79696364
Cardiotoxicity	193.44	20.66	100	36590	12139	79695559
Aplasia	187.48	20.66	85	36605	7735	79699963
Leukopenia	176.85	20.66	242	36448	116271	79591427
Renal tubular disorder	173.10	20.66	76	36614	6410	79701288
Anaemia	166.10	20.66	515	36175	444500	79263198
Neoplasm progression	165.25	20.66	158	36532	51524	79656174
Diffuse large B-cell lymphoma refractory	162.73	20.66	49	36641	1386	79706312
Cytopenia	155.73	20.66	104	36586	20279	79687419
Fall	149.52	20.66	23	36667	487606	79220092
Therapy partial responder	148.13	20.66	95	36595	17302	79690396
Cystitis haemorrhagic	148.00	20.66	76	36614	9096	79698602
Arthralgia	141.06	20.66	44	36646	571759	79135939
Salivary gland cancer	138.92	20.66	34	36656	426	79707272
Neutropenic sepsis	131.44	20.66	105	36585	26959	79680739
Sepsis	129.69	20.66	342	36348	269086	79438612
Fatigue	124.83	20.66	147	36543	929580	78778118
Cytokine release syndrome	120.68	20.66	113	36577	35885	79671813
Malignant transformation	118.61	20.66	37	36653	1181	79706517
Tumour lysis syndrome	116.51	20.66	93	36597	23846	79683852
Nephropathy toxic	116.12	20.66	87	36603	20332	79687366
Disease recurrence	115.47	20.66	121	36569	43988	79663710
Dizziness	109.17	20.66	53	36637	526388	79181310
Pyrexia	103.93	20.66	598	36092	678111	79029587
Osteosarcoma	103.70	20.66	26	36664	362	79707336
Pain	102.36	20.66	104	36586	703698	79004000
Septic shock	102.08	20.66	194	36496	122607	79585091
Product dose omission issue	100.15	20.66	3	36687	247534	79460164
Rash	95.36	20.66	76	36614	578282	79129416
Abdominal discomfort	94.83	20.66	5	36685	250722	79456976
Metastases to lymph nodes	94.05	20.66	59	36631	10338	79697360
Nasopharyngitis	93.16	20.66	6	36684	253875	79453823
B-cell lymphoma recurrent	87.51	20.66	28	36662	972	79706726
Metastases to lung	87.19	20.66	70	36620	18093	79689605
Fanconi syndrome acquired	86.53	20.66	36	36654	2658	79705040
Peripheral swelling	84.19	20.66	12	36678	269605	79438093
Insomnia	83.78	20.66	8	36682	245162	79462536
Headache	83.72	20.66	107	36583	653665	79054033
Posterior reversible encephalopathy syndrome	83.32	20.66	80	36610	26201	79681497
Weight increased	82.86	20.66	14	36676	277372	79430326
Blood lactate dehydrogenase increased	81.02	20.66	95	36595	39075	79668623
Neoplasm recurrence	80.02	20.66	39	36651	4175	79703523
Dyspnoea	77.81	20.66	175	36515	856850	78850848
Blood stem cell transplant failure	77.10	20.66	22	36668	513	79707185
Drug hypersensitivity	73.58	20.66	23	36667	298893	79408805
Anal inflammation	70.26	20.66	26	36664	1404	79706294
Rhabdomyosarcoma recurrent	67.82	20.66	15	36675	116	79707582
Pneumothorax	67.60	20.66	74	36616	28249	79679449
Myeloid leukaemia	66.10	20.66	21	36669	712	79706986
Pruritus	64.78	20.66	52	36638	394596	79313102
Metastases to peritoneum	64.16	20.66	34	36656	4338	79703360
Platelet count decreased	63.93	20.66	216	36474	194448	79513250
Ovarian disorder	61.03	20.66	18	36672	473	79707225
Musculoskeletal stiffness	59.02	20.66	6	36684	175002	79532696
Pain in extremity	58.62	20.66	49	36641	364489	79343209
Drug resistance	58.49	20.66	84	36606	42129	79665569
Hypersensitivity	58.03	20.66	24	36666	262215	79445483
Myocardial infarction	57.92	20.66	8	36682	184121	79523577
Acute lymphocytic leukaemia	57.40	20.66	33	36657	4936	79702762
Delayed puberty	57.01	20.66	14	36676	178	79707520
Premature menopause	56.84	20.66	18	36672	604	79707094
Contusion	56.13	20.66	3	36687	148773	79558925
Subdural hygroma	56.08	20.66	17	36673	492	79707206
Hypogammaglobulinaemia	56.05	20.66	47	36643	12904	79694794
Malaise	55.83	20.66	87	36603	489782	79217916
Immune effector cell-associated neurotoxicity syndrome	54.95	20.66	34	36656	5814	79701884
Stomatitis	54.63	20.66	170	36520	146587	79561111
Swelling	54.53	20.66	16	36674	216695	79491003
Blood pressure increased	54.30	20.66	15	36675	211345	79496353
Therapeutic product effect decreased	54.27	20.66	6	36684	163857	79543841
Urticaria	53.86	20.66	10	36680	185191	79522507
Cough	53.41	20.66	54	36636	366735	79340963
Lymphopenia	53.28	20.66	68	36622	30489	79677209
Drug ineffective	53.03	20.66	742	35948	1080171	78627527
Arthropathy	52.73	20.66	9	36681	177102	79530596
Myalgia	49.94	20.66	12	36678	185629	79522069
SARS-CoV-2 test negative	49.77	20.66	20	36670	1351	79706347
Progressive multifocal leukoencephalopathy	49.47	20.66	54	36636	20546	79687152
Venoocclusive disease	49.19	20.66	29	36661	4544	79703154
Chest pain	49.11	20.66	35	36655	282269	79425429
Condition aggravated	48.96	20.66	98	36592	501026	79206672
Neutrophil count decreased	48.93	20.66	123	36567	93836	79613862
Device related infection	48.62	20.66	69	36621	34225	79673473
Gene mutation	48.44	20.66	24	36666	2662	79705036
Metastases to muscle	48.29	20.66	14	36676	346	79707352
Metastases to spleen	48.12	20.66	16	36674	628	79707070
Injection site pain	47.81	20.66	3	36687	129835	79577863
Lymphoma	47.66	20.66	49	36641	17411	79690287
Ganglioneuroblastoma	47.21	20.66	9	36681	29	79707669
Metastases to breast	46.71	20.66	13	36677	276	79707422
Stem cell transplant	46.56	20.66	26	36664	3678	79704020
Sinusitis	46.40	20.66	16	36674	195485	79512213
Systemic candida	45.95	20.66	32	36658	6674	79701024
Anxiety	45.65	20.66	29	36661	248483	79459215
Recurrent cancer	45.43	20.66	23	36667	2670	79705028
Urinary tract infection	45.23	20.66	36	36654	274476	79433222
Metastases to liver	44.70	20.66	60	36630	28254	79679444
Encephalitis enteroviral	44.64	20.66	11	36679	142	79707556
Diffuse large B-cell lymphoma	44.32	20.66	40	36650	12109	79695589
Abdominal pain upper	44.11	20.66	24	36666	223795	79483903
Renal impairment	44.01	20.66	166	36524	157617	79550081
Inappropriate schedule of product administration	43.98	20.66	5	36685	133623	79574075
Muscle spasms	43.77	20.66	13	36677	174717	79532981
Agranulocytosis	43.54	20.66	76	36614	44954	79662744
Leukoencephalopathy	43.34	20.66	33	36657	7896	79699802
Discomfort	43.15	20.66	4	36686	125613	79582085
Cellulitis gangrenous	42.42	20.66	12	36678	271	79707427
T-cell lymphoma refractory	42.26	20.66	9	36681	57	79707641
Staphylococcal infection	42.25	20.66	87	36603	58208	79649490
Hepatitis B reactivation	41.51	20.66	29	36661	6079	79701619
Arachnoiditis	41.30	20.66	15	36675	768	79706930
Nephrogenic diabetes insipidus	41.27	20.66	20	36670	2114	79705584
Leukoerythroblastosis	41.26	20.66	12	36678	300	79707398
Renal tubular injury	41.18	20.66	18	36672	1501	79706197
Cardiac failure congestive	40.74	20.66	8	36682	142394	79565304
Respiratory failure	40.66	20.66	178	36512	180733	79526965
Metastases to bone marrow	40.59	20.66	15	36675	807	79706891
Candida infection	40.25	20.66	67	36623	38147	79669551
Infusion related reaction	39.44	20.66	29	36661	230208	79477490
Bacteraemia	39.29	20.66	61	36629	32763	79674935
Mobility decreased	39.15	20.66	5	36685	122170	79585528
Azoospermia	38.88	20.66	10	36680	155	79707543
Meningitis tuberculous	38.36	20.66	16	36674	1189	79706509
Multiple organ dysfunction syndrome	38.19	20.66	132	36558	120114	79587584
Ameloblastoma	38.18	20.66	9	36681	95	79707603
Cardiomyopathy	38.03	20.66	56	36634	28718	79678980
Venoocclusive liver disease	37.62	20.66	36	36654	11735	79695963
Depression	37.53	20.66	27	36663	216763	79490935
Haemophagocytic lymphohistiocytosis	37.14	20.66	48	36642	21789	79685909
Palpitations	36.46	20.66	7	36683	126603	79581095
Polyneuropathy	36.33	20.66	50	36640	24101	79683597
Myelopathy	36.25	20.66	24	36666	4609	79703089
Bronchitis	36.01	20.66	8	36682	130636	79577062
Ejection fraction decreased	35.58	20.66	60	36630	34517	79673181
White blood cell count decreased	35.49	20.66	176	36514	188112	79519586
Basal cell naevus syndrome	34.78	20.66	7	36683	32	79707666
Metastases to retroperitoneum	34.07	20.66	11	36679	393	79707305
Gastrooesophageal reflux disease	34.05	20.66	4	36686	104242	79603456
Hyperhidrosis	33.27	20.66	14	36676	151478	79556220
Musculoskeletal pain	33.26	20.66	4	36686	102350	79605348
Amniotic fluid index decreased	33.20	20.66	6	36684	13	79707685
Overdose	33.14	20.66	22	36668	184184	79523514
Drug clearance decreased	32.94	20.66	20	36670	3307	79704391
Aspergillus infection	32.40	20.66	42	36648	19119	79688579
Influenza	31.81	20.66	10	36680	129596	79578102
Pericarditis	31.68	20.66	5	36685	104231	79603467
Therapy non-responder	31.67	20.66	104	36586	92201	79615497
Herpes simplex	31.11	20.66	33	36657	12154	79695544
Oesophageal candidiasis	31.00	20.66	29	36661	9189	79698509
Transformation to acute myeloid leukaemia	30.94	20.66	13	36677	984	79706714
Proctalgia	30.86	20.66	30	36660	9971	79697727
Myelitis	30.65	20.66	17	36673	2374	79705324
Hepatic enzyme increased	30.00	20.66	24	36666	182586	79525112
Hospitalisation	29.85	20.66	4	36686	94232	79613466
Blood glucose increased	29.82	20.66	8	36682	114967	79592731
Autoimmune neutropenia	29.80	20.66	11	36679	590	79707108
Neutropenic colitis	29.54	20.66	23	36667	5684	79702014
Nervous system disorder	29.51	20.66	48	36642	26808	79680890
Rhabdomyosarcoma	29.39	20.66	8	36682	156	79707542
Glossodynia	29.15	20.66	6	36684	103331	79604367
Metastases to meninges	29.01	20.66	19	36671	3582	79704116
Metastases to heart	28.89	20.66	9	36681	286	79707412
Synovial sarcoma	28.88	20.66	7	36683	84	79707614
Vulvovaginitis	28.59	20.66	9	36681	296	79707402
Gait disturbance	28.55	20.66	32	36658	207474	79500224
Adenoviral hepatitis	28.47	20.66	12	36678	915	79706783
Periorbital cellulitis	28.37	20.66	12	36678	923	79706775
Hyperkalaemia	27.77	20.66	9	36681	114389	79593309
Quadriplegia	27.74	20.66	18	36672	3342	79704356
Post-acute COVID-19 syndrome	27.66	20.66	10	36680	505	79707193
Tubulointerstitial nephritis	27.62	20.66	57	36633	38178	79669520
Dyspepsia	27.37	20.66	8	36682	108679	79599019
Hypertension	27.20	20.66	71	36619	330921	79376777
Drug intolerance	27.19	20.66	50	36640	264069	79443629
Impaired healing	27.10	20.66	4	36686	87651	79620047
Lymphadenopathy	26.97	20.66	69	36621	53178	79654520
Oxygen saturation decreased	26.66	20.66	13	36677	129034	79578664
Adenovirus reactivation	26.44	20.66	9	36681	380	79707318
Abdominal distension	26.36	20.66	11	36679	119639	79588059
Synovial sarcoma metastatic	26.26	20.66	5	36685	16	79707682
Salivary gland neoplasm	26.14	20.66	7	36683	128	79707570
Feeling abnormal	26.05	20.66	21	36669	159178	79548520
Chromosome analysis abnormal	25.96	20.66	8	36682	245	79707453
Oedema peripheral	25.75	20.66	48	36642	252240	79455458
Diabetes mellitus	25.62	20.66	3	36687	78387	79629311
Balance disorder	25.40	20.66	7	36683	98850	79608848
Hypoaesthesia	25.40	20.66	27	36663	179325	79528373
Human herpesvirus 8 infection	25.31	20.66	12	36678	1208	79706490
Hypophosphataemia	25.23	20.66	38	36652	19875	79687823
Deafness	25.04	20.66	39	36651	20998	79686700
Ovarian failure	25.02	20.66	10	36680	666	79707032
Asthenia	24.93	20.66	136	36554	511553	79196145
Ascites	24.90	20.66	84	36606	75478	79632220
Incorrect dose administered	24.88	20.66	3	36687	76627	79631071
Cerebrovascular accident	24.77	20.66	21	36669	155271	79552427
Escherichia bacteraemia	24.72	20.66	22	36668	6540	79701158
Hypoalbuminaemia	24.68	20.66	39	36651	21258	79686440
Angioedema	24.63	20.66	3	36687	76032	79631666
Sarcoma metastatic	24.53	20.66	6	36684	75	79707623
Pneumonia adenoviral	24.02	20.66	9	36681	503	79707195
Cardio-respiratory arrest	23.87	20.66	10	36680	108500	79599198
Heart rate increased	23.69	20.66	13	36677	120711	79586987
Disorientation	23.60	20.66	73	36617	62703	79644995
Clostridium difficile infection	23.39	20.66	57	36633	42628	79665070
Scedosporium infection	23.13	20.66	12	36678	1466	79706232
Recall phenomenon	23.03	20.66	11	36679	1126	79706572
Encephalitis cytomegalovirus	22.91	20.66	11	36679	1139	79706559
Transdifferentiation of neoplasm	22.81	20.66	6	36684	102	79707596
Food protein-induced enterocolitis syndrome	22.80	20.66	5	36685	37	79707661
Mucoepidermoid carcinoma of salivary gland	22.76	20.66	6	36684	103	79707595
BK virus infection	22.76	20.66	24	36666	8780	79698918
Oligohydramnios	22.72	20.66	16	36674	3396	79704302
Accident	22.70	20.66	24	36666	8807	79698891
Rectal haemorrhage	22.43	20.66	4	36686	76296	79631402
Heart rate decreased	22.23	20.66	3	36687	70313	79637385
Neck pain	22.07	20.66	4	36686	75413	79632285
Osteonecrosis	22.05	20.66	46	36644	31049	79676649
Infection	21.99	20.66	188	36502	241524	79466174
Erythropenia	21.78	20.66	8	36682	423	79707275
Renal failure	21.38	20.66	162	36528	200806	79506892
Cytomegalovirus infection	21.33	20.66	55	36635	42589	79665109
Haematochezia	21.08	20.66	7	36683	87638	79620060
Ototoxicity	20.98	20.66	15	36675	3259	79704439
Myoclonus	20.89	20.66	42	36648	27618	79680080
Bradycardia	20.81	20.66	19	36671	135538	79572160
Treatment failure	20.77	20.66	142	36548	170344	79537354
Hypoacusis	20.68	20.66	44	36646	30106	79677592
Acute myocardial infarction	20.66	20.66	5	36685	77031	79630667

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L01AA06	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS ALKYLATING AGENTS Nitrogen mustard analogues
FDA MoA	N0000000236	Alkylating Activity
FDA EPC	N0000175558	Alkylating Drug
MeSH PA	D000477	Alkylating Agents
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D018906	Antineoplastic Agents, Alkylating
MeSH PA	D009676	Noxae
CHEBI has role	CHEBI:35610	antineoplastic agents
CHEBI has role	CHEBI:35703	Xenobiotic
CHEBI has role	CHEBI:35705	immunosuppressive agents
CHEBI has role	CHEBI:78298	environmental contaminants

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Testicular Germ Cell Tumor	indication
Ewing's sarcoma	off-label use	76909002	DOID:3369
Burkitt's lymphoma	off-label use	118617000
Small cell carcinoma of lung	off-label use	254632001	DOID:5409
Non-small cell lung cancer	off-label use	254637007	DOID:3908
Malignant tumor of head and/or neck	off-label use	255056009
Osteosarcoma of bone	off-label use	307576001	DOID:3376
Soft or Connective Tissue Sarcoma	off-label use
Progressive Diffuse Large B-Cell Lymphoma	off-label use
Invasive Bladder Malignancy	off-label use
Renal tubular acidosis	contraindication	1776003	DOID:14219
Hyperbilirubinemia	contraindication	14783006	DOID:2741
Dehydration	contraindication	34095006
Fanconi syndrome	contraindication	40488004	DOID:1062
Hypokalemia	contraindication	43339004
Leukopenia	contraindication	84828003	DOID:615
Kidney disease	contraindication	90708001	DOID:557
Kidney excision	contraindication	108022006
Liver function tests abnormal	contraindication	166603001
Disease of liver	contraindication	235856003	DOID:409
Impaired wound healing	contraindication	271618001
Anemia	contraindication	271737000	DOID:2355
Pregnancy, function	contraindication	289908002
Thrombocytopenic disorder	contraindication	302215000	DOID:1588
Bone marrow depression	contraindication	307762000
Coma	contraindication	371632003
Impaired cognition	contraindication	386806002
Breastfeeding (mother)	contraindication	413712001
Polyneuropathies	contraindication
CNS Toxicity	contraindication
Cancer Chemotherapy Induced Hemorrhagic Cystitis	contraindication
Severe Bone Marrow Depression	contraindication
Bone Metastases	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	1.54	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
4019476	VUID
N0000147596	NUI
D00343	KEGG_DRUG
4019476	VANDF
C0020823	UMLSCUI
CHEBI:5864	CHEBI
CHEMBL1024	ChEMBL_ID
DB01181	DRUGBANK_ID
D007069	MESH_DESCRIPTOR_UI
3690	PUBCHEM_CID
7201	IUPHAR_LIGAND_ID
2865	INN_ID
UM20QQM95Y	UNII
5657	RXNORM
44391	MMSL
4867	MMSL
d00257	MMSL
002642	NDDF
108757000	SNOMEDCT_US
386904003	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Ifosfamide	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9530	INJECTION	50 mg	INTRAVENOUS	ANDA	25 sections
Ifosfamide	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9530	INJECTION	50 mg	INTRAVENOUS	ANDA	25 sections
Ifosfamide	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9531	INJECTION	50 mg	INTRAVENOUS	ANDA	25 sections
Ifosfamide	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9531	INJECTION	50 mg	INTRAVENOUS	ANDA	25 sections
IFEX	HUMAN PRESCRIPTION DRUG LABEL	1	0338-3991	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAVENOUS	NDA	26 sections
IFEX	HUMAN PRESCRIPTION DRUG LABEL	1	0338-3991	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAVENOUS	NDA	26 sections
IFEX	HUMAN PRESCRIPTION DRUG LABEL	1	0338-3993	INJECTION, POWDER, FOR SOLUTION	3 g	INTRAVENOUS	NDA	26 sections
IFEX	HUMAN PRESCRIPTION DRUG LABEL	1	0338-3993	INJECTION, POWDER, FOR SOLUTION	3 g	INTRAVENOUS	NDA	26 sections
Ifosfamide	HUMAN PRESCRIPTION DRUG LABEL	1	0703-3427	INJECTION, SOLUTION	1 g	INTRAVENOUS	ANDA	26 sections
Ifosfamide	HUMAN PRESCRIPTION DRUG LABEL	1	0703-3429	INJECTION, SOLUTION	3 g	INTRAVENOUS	ANDA	26 sections
IFOSFAMIDE	HUMAN PRESCRIPTION DRUG LABEL	1	10019-925	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAVENOUS	NDA	26 sections
IFOSFAMIDE	HUMAN PRESCRIPTION DRUG LABEL	1	10019-925	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAVENOUS	NDA	26 sections
IFOSFAMIDE	HUMAN PRESCRIPTION DRUG LABEL	1	10019-926	INJECTION, POWDER, FOR SOLUTION	3 g	INTRAVENOUS	NDA	26 sections
IFOSFAMIDE	HUMAN PRESCRIPTION DRUG LABEL	1	10019-926	INJECTION, POWDER, FOR SOLUTION	3 g	INTRAVENOUS	NDA	26 sections
IFOSFAMIDE	HUMAN PRESCRIPTION DRUG LABEL	1	10019-927	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAVENOUS	NDA	26 sections
IFOSFAMIDE	HUMAN PRESCRIPTION DRUG LABEL	1	10019-927	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAVENOUS	NDA	26 sections
IFOSFAMIDE	HUMAN PRESCRIPTION DRUG LABEL	1	10019-929	INJECTION, POWDER, FOR SOLUTION	3 g	INTRAVENOUS	NDA	26 sections
IFOSFAMIDE	HUMAN PRESCRIPTION DRUG LABEL	1	10019-929	INJECTION, POWDER, FOR SOLUTION	3 g	INTRAVENOUS	NDA	26 sections
Ifosfamide	Human Prescription Drug Label	1	63323-142	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	26 sections
Ifosfamide	Human Prescription Drug Label	1	63323-142	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	26 sections